Drug Search Results
More Filters [+]

Camicinal

Alternative Names: camicinal, gsk962040
Latest Update: 2017-12-11
Latest Update Note: Clinical Trial Update

Product Description

Camicinal (GSK962040) is the most advanced, small-molecule, selective motilin receptor agonist with therapeutic potential to date.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25341626/)

Mechanisms of Action: Motilin receptor Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Camicinal

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Gastroparesis|Parkinson's Disease

Phase 1: Gastroparesis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01934192

P2

Terminated

Gastroparesis

2016-07-08

NCT02210000

P2

Completed

Gastroparesis

2015-08-24

GSK962040 Parkinson's disease PoC

P2

Completed

Parkinson's Disease

2014-05-01

NCT01602549

P2

Completed

Gastroparesis|Parkinson's Disease

2014-05-01

Recent News Events

Date

Type

Title